medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2013, Número 09

<< Anterior Siguiente >>

Ginecol Obstet Mex 2013; 81 (09)


Anticonceptivos de larga duración reversibles: una estrategia eficaz para la reducción de los embarazos no planeados

Lira-Plascencia J, Velázquez-Ramírez N, Ibargüengoitia-Ochoa F, Montoya-Romero JJ, Castelazo-Morales E, Valerio-Castro E

Idioma: Español
Referencias bibliográficas: 59
Paginas: 530-540
Archivo PDF: 243.77 Kb.


RESUMEN

Los anticonceptivos de larga duración, reversibles, han demostrado altas tasas de efectividad y de cumplimiento a largo plazo, con pocas contraindicaciones. Sin embargo, a pesar de que en México se dispone de una gran variedad de métodos anticonceptivos reversibles, la mayoría de las mujeres sigue recurriendo a las opciones menos eficaces. Las ventajas para la salud derivadas de la anticoncepción son importantes porque previenen el embarazo no planeado, reducen el número de abortos y la incidencia de muerte y discapacidad relacionadas con las complicaciones del embarazo y parto. El Comité de Salud Reproductiva y Derechos Sexuales de la Federación Mexicana de Colegios de Obstetricia y Ginecología (FEMECOG) realizó una revisión bibliográfica con el propósito de evaluar el uso de los métodos anticonceptivos de larga duración reversibles como una herramienta eficaz y accesible para disminuir la incidencia de embarazos no planeados y sus consecuencias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Instituto Nacional de Estadística y Geografía. Nacimientos registrados según sexo 1990 a 2011. Consultado en: http://www.inegi.org.mx/sistemas/sisept/Default. aspx?t=mdemo22&s=est&c=17525

  2. Consejo Nacional de Población. La situación demográfica de México 2011. Puede consultarse en: http://www. conapo.gob.mx/es/CONAPO/La situación demográfica de México 2011

  3. Frost IJ, Darroch JE, Remez L. Improving contraceptive use in the United States. Issues Brief (Alan Guttmacher Inst); 2008: 1-8.

  4. Jones RK, Darroch JE, Henshaw SK. Contraceptive use among U.S. women having abortions in 2001-2001. Perspect Sex Reprod Health 2002;34:294-303.

  5. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive technology.19 ed. New York: Ardent Media, 2007.

  6. Principales indicadores de salud reproductiva/ENADID 2009. Transiciones a la vida reproductiva y fecundidad. Consultado en:http://www.portal.conapo.gob.mx/ pubiicaciones/SaludReproductiva/2009/1.%20 Transiciones% 2 0de%20vida%20BIS.pdf. Consultado en marzo de 2013.

  7. Principales indicadores de salud reproductiva/ENADID 2009. Mujeres sexualmente activas. Puede consultarse en: http://www.conapo.gob.mx/work/models/CONAPO/ Resource/216/1/images/5MujeresSexualmenteActivas. pdf. Consultado en marzo 2013.

  8. Espey E, Ogburn T. Long-Acting Reversible Contraceptives. Obstet Gynecol 2011; 117: 705-719.

  9. Singh S, Darroch JE. Adding it Up: Costs and benefits of contraceptive services - Estimates for 2012, New York: Guttmacher Institute and United Nations Population Fund (UNFPA), 2012. http://www.guttmacher.org/pubs/FBCosts- Benefits-Contraceptives.html.

  10. Consultado en marzo de 2013. Observatorio de mortalidad materna en México. Muerte Materna: indicadores 2010. Consultado en: http://www.omm.org.mx/index.php/ indicadores/158.html. Consultado en marzo 2013.

  11. Estados Unidos Mexicanos, Secretaría de Salud. Resolución por la que se modifica la Norma Oficial Mexicana NOM-005-SSA2-1993, de los servicios de planificación familiar. En: http://www.salud.gob.mx/unidades/cdi/ nom/rm005ssa293.html. Consultado en marzo de 2013.

  12. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and cooper TCu 380 Ag intrauterine contraceptive device: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-77.

  13. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contraception Reprod Health Care 2008;13(S1):4- 12.

  14. Stanford JB, Mikolajczyk RT. Mechanisms of action of intrauterine devices: update and estimation of postfertilization effects. Am J Obstet Gynecol 2002;187:1699-1708.

  15. Croxatto H. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002; 65: 21-27.

  16. Organización Mundial de la Salud. Criterios médicos de elegibilidad para el uso de anticonceptivos. 4ª ed 2009. En http://whqlibdoc.who.int/publications/ 2011/9789243563886_spa.pdf. Consultado en marzo del 2013.

  17. Black K, Lotke P, Buhling KJ, Zite NB. A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women. Eur J Contracept Reprod Health Care 2012;17:340-350.

  18. Hubacher D, Lara-Ricalde R, Taylor DJ. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-567.

  19. Lyus R, Lohr P, Prager S, Board of Society of Family Planning. Use of Mlrena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 2010; 81: 367-71

  20. National Institute for Health and Clinical Excellence. Clinical Guideline 30: long-acting reversible contraception, developed by the National Collaborating Centre for Women’s and Children’s Health, October 2 0 0 5 . Disponible en: http://www.nice.org.uk/nicemedia/ live/10974/29909/29909.pdf. Consultado en abril de 2013.

  21. Mohllajee AP, Curtís KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145-153.

  22. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility follow -up after participation in a randomized clinical trial. Contraception 2007;75:88-92.

  23. Skjeldestad FE. How effectively do copper intrauterine devices prevent ectopic pregnancy? Acta Obstet Gynecol Scand 1997;76:684-690.

  24. Instituto Nacional de Estadística y Geografía. Porcentaje de nacimientos registrados de madres adolescentes (menores de 20 años) 2004 a 2011. En: http://wwvi/.inegi.org.mx/sistemas/sisept/Default. aspx?t=mdemo29&c=17528&s:=est Consultado en abril de 2013.

  25. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:90-96.

  26. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of Long-Acting Reversible Contraception. N Engl J Med 2012;366:1998-2007.

  27. Toivonen J, Luukkainen T, Alionen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years’ comparative experience of levonorgestrel and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-264.

  28. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Committe Opinión No. 450. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:1434-1438.

  29. Adolescents and Long-Acting Reversible Contraception: implants and intrauterine devices. Committe Opinion 539. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:983-988.

  30. Grimes DA, López LM, Schulz KF. Antibiotic prophylaxis for intrauterine contracptive device insertion. Cochrane Database Syst Rev. 2001 Issue 3. Art. No.: CD001327. DOI: 10.1002/14651858.CD001327. Consultado en mayo 2013.

  31. Bednarek PH, Creinin MD, Reeves MF, Cwiak CA, Espey E, Jensen JT. Inmediate versus delayed IUD insertion after uterine aspiration. N Engl J Med 2011; 364: 2208-17

  32. D’Arcangues C. Worlwide use of intrauterine devices for contraception. Contraception 2007; 75: 82-7

  33. Lara RR, Velázquez RN, Reyes ME, Baca-Olivo PR. Dispositivo intrauterino posplacenta. Hilos guía no visibles. Ginecol Obstet Mex 2012; 80: 201-207.

  34. Grimes DA, López LM, Shuiz KF, Stanwood NL. Immediate postabortal insertion or intrauterine devices. Combination oral contraceptives. Cochrane Database Syst Rev. 2010, Issue 6. Artículo: CD001777 consultado en mayo 2013.

  35. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) a systematic enquiry and overview. Eur J Obstet Gynecol Repod Biol 2006; 125:9-28.

  36. Aslam N, Blunt S. Latthe P. Effectiveness and tolerability of levonorgestrel intrauterine system in adolescents. J Obstet Gynecol 2010;30:489-491.

  37. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006; 125:9-28.

  38. Kaislasuo J, Suhonen S, Gissler M, Lähteenmäki P, Heikinheimo O. Uterine perforation caused by intrauterine devices: clinical course and treatment. Hum Reprod; 2013: Mar 22 (Epub ahead of print). Consultado en mayo 2013: http://www.ncbi.nlm.nih.gov/pubmed/23526304

  39. Marions L, Lövkvist L, Taube A, Johansson M, Dalvik H, Overlie I. Use of the levonorgestrel releasing intrauterine system in nulliparous women - a non-interventional study in Sweden. Eur J Contraception and Reprod Health Care 2011;16:126-134.

  40. National Institute for Health and Clinical Excellence. Clinical Guideline 30: long-acting reversible contraception, developed by the National Collaborating Centre for Women’s and Children’s Health, October2005. Disponible en: http://www.nice.org.uk/nicemedia/ live/10974/29909/29909.pdf. Consultado en mayo 2013.

  41. Andersson K, Odiind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) lUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.

  42. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-years report. J Fam Plann Repord Health Care 2002;28:73-77.

  43. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 59, January 2005. Intrauterine device. Obstet Gynecol 2005;105:223-232.

  44. Heinemann K, Assman A, Dinger J, Westhof C. Intrauterine devices and the risk of uterine perforations: interim results from the EURAS-IUD study: Poster presented at the American Congress of Obstetricians and Gynecologist (ACOG) 58th Annual Clinical Meeting, May 15-19; San Francisco, California, USA, 2010.

  45. Ronnerdag M, OdLind V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception 2007;75:268-270.

  46. Petersen KR, Brooks L, Jacobsen N, Skoby SO. Clinical performance of intrauterine devices in nulligravidae: is the length of endometrial cavity of significance? Acta Eur Fértil 1991;22:225-228.

  47. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as contraceptive choice for teenage mothers: a comparision of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010;81:421-426.

  48. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, Thaithumyanon P, Punnahitananda S, TosukhowongP, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding com pared to those of an intrauterine device). Contraception 2000;62:239-246.

  49. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva da Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519-520.

  50. Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (2009). Consultado en mayo 2003: http://www.fsrh.org/pdfs/ UKMEC2009.pdf

  51. Otero-Flores J, Balderas M, Bonilla C, Vázquez-estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynecol Obstet 2005; 90:228-233.

  52. Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007;50:907-917.

  53. Graesslin O, Korver T. The contraceptive efficacy of Implanon: A review of clinical trials and marketing experience. Eur J Contraception Reprod Health Care 2008;13:4-12.

  54. Walch K, Unfried G, Huber J, Kurz C, van Trostsenburg M, Pernicka E, Wenzl R. Implanon versus medroxyprogesterone acetate: effect on pain scores in patients with symptomatic endometriosis, a pilot study. Contraception 2009;79:29-34.

  55. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a songle-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91: 1646-1653.

  56. Shukman LP, Gabriel H. Management and localization strategies for nonpable Implanon rod. Contraception 2006;73:325-330.

  57. Ficha técnica de Implanon NXT. Merck Sharp & Dohme. Consultado en mayo de 2013: http://www.msd.es/documentos/ profesionales-sanitarios/ps-implanon-ft.pdf

  58. Mansour D, Korver T, Merintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Health Care 2008;13:13-28.

  59. Deokar AM, Jackson W, Ornar HA. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant. Int J Adolesc Med Health 2011;23:75-77.




2020     |     www.medigraphic.com